Product Description
Briquilimab is a targeted, humanized monoclonal antibody in development as a therapeutic to deplete diseased mast and stem cells as well as a conditioning agent to clear hematopoietic stem cells from bone marrow prior to transplant. By blocking signaling through the c-Kit receptor, briquilimab leads to depletion of diseased mast cells in the skin and diseased stem cells in the bone marrow. (Sourced from: https://www.jaspertherapeutics.com/jsp191/)
Mechanisms of Action: CD117 Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation:
Fast Track - Severe Combined Immunodeficiency|Allogeneic Stem Cell Transplant|Hematopoietic Stem Cell Transplant|Stem Cell Transplant
Orphan Drug - Stem Cell Transplant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jasper Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Germany, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Chronic Inducible Urticaria|Chronic Spontaneous Urticaria|Severe Combined Immunodeficiency|Urticaria
Phase 1: Asthma, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JSP-CP-014 | P2 |
Unknown Status |
Urticaria |
2029-12-07 |
|
| JSP-CP-014 | P2 |
Enrolling by invitation |
Urticaria |
2026-12-01 |
|
| BEACON | P2 |
Recruiting |
Chronic Spontaneous Urticaria |
2026-04-01 |
|
| JSP-CP-010 | P2 |
Unknown Status |
Chronic Inducible Urticaria |
2025-12-22 |